Valeo Financial Advisors LLC Has $455,000 Position in Edwards Lifesciences Corporation $EW

Valeo Financial Advisors LLC lifted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 13.2% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,813 shares of the medical research company’s stock after acquiring an additional 677 shares during the period. Valeo Financial Advisors LLC’s holdings in Edwards Lifesciences were worth $455,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Jennison Associates LLC lifted its position in shares of Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock valued at $731,036,000 after acquiring an additional 2,576,383 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Edwards Lifesciences by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock valued at $491,673,000 after acquiring an additional 264,311 shares during the period. Nuveen LLC acquired a new position in shares of Edwards Lifesciences during the 1st quarter valued at $330,881,000. Invesco Ltd. raised its holdings in Edwards Lifesciences by 2.6% during the first quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock worth $310,773,000 after buying an additional 107,241 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Edwards Lifesciences by 5.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock worth $287,140,000 after buying an additional 198,882 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $75.75 on Thursday. The firm has a market cap of $44.47 billion, a price-to-earnings ratio of 10.90, a P/E/G ratio of 3.69 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a 52 week low of $64.89 and a 52 week high of $83.00. The firm’s 50-day simple moving average is $78.28 and its two-hundred day simple moving average is $76.05.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the business earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on EW shares. Canaccord Genuity Group upped their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock a “hold” rating in a report on Friday, July 25th. Barclays upped their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, July 25th. William Blair upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a report on Friday, July 25th. BTIG Research upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Tuesday, July 29th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $87.06.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.